Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.85 | 1.36 |
NAV | ₹32.79 | ₹200.30 |
Fund Started | 08 Jan 2018 | 07 May 2007 |
Fund Size | ₹4260.02 Cr | ₹92168.85 Cr |
Exit Load | Exit load of 1% if redeemed within 3 months. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -4.15% | 4.04% |
3 Year | 22.47% | 24.63% |
5 Year | 23.96% | 25.63% |
1 Year
3 Year
5 Year
Equity | 95.46% | 93.94% |
Cash | 4.54% | 6.06% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Indian Bank | 3.26% |
Glenmark Pharmaceuticals Ltd. | 2.97% |
Blue Star Ltd. | 2.48% |
IDFC First Bank Ltd. | 2.48% |
Max Financial Services Ltd. | 2.48% |
UNO Minda Ltd. | 2.34% |
Tube Investments Of India Ltd. | 2.22% |
JK Cement Ltd. | 2.20% |
Union Bank of India | 2.20% |
Nippon Life India Asset Management Ltd. | 2.17% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.46% |
AU Small Finance Bank Ltd. | 3.70% |
Indian Bank | 3.54% |
The Federal Bank Ltd. | 3.38% |
Balkrishna Industries Ltd. | 3.37% |
Fortis Healthcare Ltd. | 3.19% |
Coforge Ltd. | 3.11% |
Hindustan Petroleum Corporation Ltd. | 2.96% |
Glenmark Pharmaceuticals Ltd. | 2.67% |
Ipca Laboratories Ltd. | 2.52% |
Name | Krishna Sanghavi | Chirag Setalvad |
Start Date | 07 Feb 2025 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation & provide long-term growth opportunities by investing in a portfolio constituted of equity & equity related securities and derivatives predominantly in mid cap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 08 Jan 2018 | 07 May 2007 |
Description
Launch Date